S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
China fines former NBA star Lin over quarantine comments
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
China fines former NBA star Lin over quarantine comments
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
China fines former NBA star Lin over quarantine comments
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
China fines former NBA star Lin over quarantine comments
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
NASDAQ:KNSA

Kiniksa Pharmaceuticals - KNSA Stock Forecast, Price & News

$16.67
-0.38 (-2.23%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$16.12
$16.90
50-Day Range
$11.06
$17.05
52-Week Range
$7.36
$17.19
Volume
256,089 shs
Average Volume
332,840 shs
Market Capitalization
$1.16 billion
P/E Ratio
8.34
Dividend Yield
N/A
Price Target
$34.00

Kiniksa Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
104.0% Upside
$34.00 Price Target
Short Interest
Bearish
4.01% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.64mentions of Kiniksa Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$354,638 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.29) to ($0.98) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

327th out of 1,052 stocks

Pharmaceutical Preparations Industry

144th out of 514 stocks

KNSA stock logo

About Kiniksa Pharmaceuticals (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

Receive KNSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KNSA Stock News Headlines

Recap: Kiniksa Pharmaceuticals Q3 Earnings
See More Headlines
Receive KNSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KNSA Company Calendar

Last Earnings
11/01/2021
Today
12/02/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/28/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KNSA
Fax
N/A
Employees
215
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$34.00
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+104.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-157,920,000.00
Pretax Margin
-18.00%

Debt

Sales & Book Value

Annual Sales
$38.54 million
Book Value
$5.52 per share

Miscellaneous

Free Float
31,588,000
Market Cap
$1.16 billion
Optionable
Not Optionable
Beta
-0.14

Key Executives

  • Mr. Sanj K. Patel (Age 52)
    CEO & Chairman
    Comp: $1.61M
  • Dr. John F. Paolini (Age 57)
    Sr. VP & Chief Medical Officer
    Comp: $710.86k
  • Mr. Mark Ragosa C.F.A. (Age 47)
    Sr. VP & CFO
  • Mr. Eben Tessari (Age 40)
    Sr. VP & COO
  • Mr. Michael R. Megna CPA (Age 51)
    Chief Accounting Officer & Group VP of Fin.
  • Ms. Mei Jang
    Sr. VP of Technical Operations
  • Rachel Frank
    Associate Director of Investor Relations
  • Mr. Chad Morin
    Sr. VP, Chief Compliance Officer & Data Protection Officer
  • Ms. Madelyn Zeylikman
    SVP, Gen. Counsel & Sec.
  • Ms. Melissa Manno
    SVP & Chief HR Officer













KNSA Stock - Frequently Asked Questions

Should I buy or sell Kiniksa Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KNSA shares.
View KNSA analyst ratings
or view top-rated stocks.

What is Kiniksa Pharmaceuticals' stock price forecast for 2023?

1 analysts have issued twelve-month price objectives for Kiniksa Pharmaceuticals' stock. Their KNSA share price forecasts range from $34.00 to $34.00. On average, they anticipate the company's stock price to reach $34.00 in the next year. This suggests a possible upside of 104.0% from the stock's current price.
View analysts price targets for KNSA
or view top-rated stocks among Wall Street analysts.

How have KNSA shares performed in 2022?

Kiniksa Pharmaceuticals' stock was trading at $11.77 at the beginning of 2022. Since then, KNSA stock has increased by 41.6% and is now trading at $16.67.
View the best growth stocks for 2022 here
.

When is Kiniksa Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our KNSA earnings forecast
.

How were Kiniksa Pharmaceuticals' earnings last quarter?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) announced its quarterly earnings results on Monday, November, 1st. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.21. The firm had revenue of $12.10 million for the quarter, compared to the consensus estimate of $9.92 million. Kiniksa Pharmaceuticals had a net margin of 80.53% and a negative trailing twelve-month return on equity of 15.66%.

What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO?

1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Kiniksa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD).

When did Kiniksa Pharmaceuticals IPO?

(KNSA) raised $126 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Kiniksa Pharmaceuticals' stock symbol?

Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."

Who are Kiniksa Pharmaceuticals' major shareholders?

Kiniksa Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.22%), Vanguard Group Inc. (4.43%), Pictet Asset Management SA (4.37%), Rubric Capital Management LP (2.08%), Rice Hall James & Associates LLC (1.08%) and State Street Corp (0.88%). Insiders that own company stock include Barry D Quart, John F Paolini, Sanj K Patel and Thomas W Beetham.
View institutional ownership trends
.

How do I buy shares of Kiniksa Pharmaceuticals?

Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kiniksa Pharmaceuticals' stock price today?

One share of KNSA stock can currently be purchased for approximately $16.67.

How much money does Kiniksa Pharmaceuticals make?

Kiniksa Pharmaceuticals (NASDAQ:KNSA) has a market capitalization of $1.16 billion and generates $38.54 million in revenue each year. The company earns $-157,920,000.00 in net income (profit) each year or $2.00 on an earnings per share basis.

How many employees does Kiniksa Pharmaceuticals have?

The company employs 215 workers across the globe.

How can I contact Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The official website for the company is www.kiniksa.com. The company can be reached via phone at 448081896257 or via email at ir@kiniksa.com.

This page (NASDAQ:KNSA) was last updated on 12/3/2022 by MarketBeat.com Staff